Quantcast

CureMD to Showcase Its Advanced Oncology EHR at Upcoming ASCO 2013 Meeting in Chicago

May 30, 2013

CureMD announced today its plans to create a new technology paradigm in the Oncology field by offering medical oncologists and their staffs an affordable Cloud Based solution to automate all clinical, administrative, and financial aspects of their busy practices.

New York, NY (PRWEB) May 30, 2013

CureMD, a healthcare technology company with headquarters in New York City, has recently completed a 5 year development project which has resulted in the industry´s first and only chemotherapy administration module found within a truly web native CCHIT, ONC certified electronic health record solution for medical oncologists. The privately held firm, founded in 1997, provides an affordable, adaptable, and accessible all-in-one solution to more than 4,000 providers across 35 specialties for substantially less than traditional client server price points.

“We are excited to bring unprecedented functionality to practicing medical oncologists at a fraction of the cost previously required to automate the documentation of their daily workflows,” said Kamal Hashmat at CureMD. “The Cloud allows us to bring this possibility to the marketplace. I am proud of the Kabot-CureMD development team which has worked hard over the past year to bring this possibility to the marketplace.”

Arif Toor, MD, the newly appointed Chairman of the CureMD Oncology division, was formerly the founder and chairman of Kabot Oncology Systems, a company acquired by CureMD in late 2012 to facilitate the enhancement of the CureMD solution. According to Toor, physicians are now able to use evidence based, disease related, chemotherapy regimens for ordering therapy from within the system. The chemotherapy management module ensures delivery of complete information to the nurse for administration including required number of vials, dosages in milligrams, and quantities in exact milliliters to be infused with wastage calculations, if any. “CureMD Oncology prevents losses due to missed charges and will enhance savings by eliminating labor required to enter/re-enter charge data for billing – something we are very serious about preserving for our clients in this age of lower reimbursements, rising costs, and increased regulatory burdens for practitioners,” said Toor.

All attendees are encouraged to visit CureMD´s booth # 4032 in the technology aisle at McCormick Center in Chicago during the exhibit hours on Saturday, June 1, 2013 through Monday June, 3, 2013. A special acquisition fee of less than 10K per physician and hundreds, not thousands of dollars for a monthly subscription will be announced at the event. Furthermore, by choosing to use the CureBilling option, an in-house billing service operation established in 2006 which now serves over 400 CureMD providers from across 70 groups using the CureMD All-in-One solution, oncologists are able to receive the Advanced Oncology EHR solution for free.

About The American Society of Clinical Oncologists (ASCO)

ASCO is a non-profit organization founded in 1964 with the overarching goal of improving cancer care and prevention. Nearly 30,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and healthcare professionals at all levels of the practice of oncology.

About CureMD

CureMD is a New York based, award winning network of health information management systems and services, offering certified EHR, practice management, patient portal, revenue cycle management, and transcription to help accelerate adoption and Meaningful Use qualification — driving outcomes and subsidy payments to maximize value and returns. CureMD´s advanced web technology and award-winning usability facilitate quality decision making, streamline operations, and ensure compliance.

For more information, email sales(at)curemd(dot)com, call1-866-6-GET EMR to speak with a representative or follow us on twitter.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/5/prweb10777852.htm


Source: prweb



comments powered by Disqus